Progyny, Inc. (NASDAQ:PGNY) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $27.9091.

PGNY has been the subject of several research reports. Barclays reduced their price objective on Progyny from $29.00 to $23.00 and set an “overweight” rating for the company in a report on Friday, March 20th. Jefferies Financial Group reiterated a “buy” rating and set a $30.00 price target on shares of Progyny in a research note on Friday, March 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. KeyCorp dropped their price objective on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Finally, Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the business’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80. Following the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at $1,563,894.60. The trade was a 4.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 7,455 shares of company stock valued at $129,515. 9.40% of the stock is currently owned by insiders.

Institutional Trading of Progyny

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new position in Progyny during the 4th quarter valued at about $25,000. Federated Hermes Inc. boosted its position in shares of Progyny by 147.3% in the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after acquiring an additional 819 shares during the period. Hantz Financial Services Inc. boosted its position in shares of Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after acquiring an additional 742 shares during the period. Versant Capital Management Inc grew its stake in Progyny by 61.8% during the third quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock valued at $50,000 after acquiring an additional 894 shares in the last quarter. Finally, Covestor Ltd increased its holdings in Progyny by 164.9% during the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock worth $56,000 after acquiring an additional 1,624 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $17.27 on Monday. The company has a market capitalization of $1.41 billion, a P/E ratio of 26.57, a price-to-earnings-growth ratio of 1.00 and a beta of 1.01. The company’s 50-day moving average is $20.60 and its 200 day moving average is $22.36. Progyny has a fifty-two week low of $16.75 and a fifty-two week high of $28.75.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The business had revenue of $318.40 million for the quarter, compared to analyst estimates of $314.26 million. During the same quarter in the previous year, the firm posted $0.42 earnings per share. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, research analysts predict that Progyny will post 0.6 earnings per share for the current year.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.